MR-MC-01 / Mirae Cell Bio - LARVOL DELTA

A single-center, phase 1/2a trial of hESC-derived mesenchymal stem cells (MR-MC-01) for safety and efficacy in interstitial cystitis patients. (PubMed, Stem Cells Transl Med) - P1 | "Further large-scale, long-term studies are warranted to confirm these results and optimize therapeutic protocols. (Identifier: NCT04610359)."

Clinical • Journal • P1/2 data • Hematological Disorders • Interstitial Cystitis • Pain

Safety of Human Embryonic Stem Cell-derived Mesenchymal Stem Cells for Treating Interstitial Cystitis: A Phase I Study. (PubMed, Stem Cells Transl Med) - "This study aimed to investigate the safety of the clinical-grade mesenchymal stem cells (MSCs) derived from human embryonic stem cells (hESCs), code name MR-MC-01 (SNU42-MMSCs), in IC patients...hESC-based therapeutics was safe and proved to have potential therapeutic efficacy in IC patients. Stem cell therapy could be a potential therapeutic option for treating IC."

Journal • P1 data • Anesthesia • Interstitial Cystitis • Pain